Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/23554| Title: | Pembrolizumab in relapsed or refractory Richter syndrome. | Austin Authors: | Armand, Philippe;Murawski, Niels;Molin, Daniel;Zain, Jasmine;Eichhorst, Barbara;Gulbas, Zafer;Hawkes, Eliza A ;Pagel, John M;Phillips, Tycel;Ribrag, Vincent;Svoboda, Jakub;Stathis, Anastasios;Chatterjee, Arkendu;Orlowski, Robert;Marinello, Patricia;Christian, Beth | Affiliation: | Oncology Institute of Southern Switzerland, Bellinzona, Switzerland Dana-Farber Cancer Institute, Boston, MA, USA Merck & Co., Inc, Kenilworth, NJ, USA City of Hope, Duarte, CA, USA Swedish Center for Blood Disorders and Stem Cell Transplants, Swedish Cancer Institute, Seattle, WA, USA University of Cologne, Cologne, Germany Rogel Cancer Center, Ann Arbor, MI, USA The James Cancer Hospital and Solove Research Institute, Ohio State University, Columbus, OH, USA Perelman Center for Advanced Medicine, University of Pennsylvania, Philadelphia, PA, USA Anadolu Medical Center, Istanbul, Turkey Universitäts-klinikum des Saarlandes Innere Medizin I, Homburg, Germany Olivia Newton-John Cancer Wellness and Research Centre, Austin Health, Heidelberg, Victoria, Australia Experimental and Clinical Oncology, Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.. Institut Gustave Roussy, Villejuif, France |
Issue Date: | 16-Jun-2020 | Date: | 2020-07 | Publication information: | British Journal of Haematology 2020; 190(2): e117-e120 | URI: | https://ahro.austin.org.au/austinjspui/handle/1/23554 | DOI: | 10.1111/bjh.16762 | ORCID: | 0000-0001-6098-1603 0000-0002-0376-2559 0000-0003-2143-9672 0000-0002-5221-353X |
Journal: | British Journal of Haematology | PubMed URL: | 32544980 | Type: | Journal Article | Subjects: | PD-1 Richter syndrome chronic lymphocytic leukaemia immunotherapy pembrolizumab |
| Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.